Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CODEPREX vs BENZONATATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Codeine is a prodrug converted to morphine via CYP2D6; morphine acts as a mu-opioid receptor agonist, while homatropine is an anticholinergic that reduces respiratory secretions.
Benzonatate is a local anesthetic structurally related to tetracaine. It suppresses cough by anesthetizing stretch receptors in the respiratory tract, reducing the cough reflex.
Cough suppression (FDA-approved)
Symptomatic relief of cough
Adults: 1 tablet (containing 5 mg hydrocodone and 325 mg acetaminophen) orally every 4-6 hours as needed for pain; maximum 6 tablets per day.
100 mg to 200 mg orally three times daily as needed for cough.
4-6 hours (prolonged to 10-12 hours in hepatic impairment)
Terminal elimination half-life is approximately 3–8 hours in adults; prolonged in hepatic impairment.
Codeine undergoes O-demethylation via CYP2D6 to morphine; also N-demethylation to norcodeine via CYP3A4; homatropine is minimally metabolized.
Metabolized by plasma esterases (including pseudocholinesterase) to tetracaine and other metabolites.
Renal: 60% as unchanged drug; Hepatic metabolism: 30% (inactive metabolites); Fecal: 10%
Primarily renal excretion of metabolites; unchanged benzonatate is negligible. Fecal elimination accounts for <5%. Biliary excretion is minimal.
92% (primarily to albumin)
Approximately 75–85% bound primarily to albumin.
1.5-2.0 L/kg (extensive tissue distribution)
Approximately 3.5 L/kg, indicating extensive tissue distribution.
Oral: 70-80% (first-pass metabolism reduces from 100% IV)
Oral: Estimated 20–30% due to extensive first-pass metabolism.
Hydrocodone: GFR 30-80 m L/min: no adjustment; GFR 10-29 m L/min: reduce dose by 50% or extend interval to every 8-12 hours; GFR <10 m L/min: use with caution, consider alternative. Acetaminophen: GFR <10 m L/min: extend dosing interval to every 8 hours.
No specific dosage adjustment is recommended for renal impairment per manufacturer; however, caution and monitoring are advised.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50% and extend interval to every 8 hours; Class C: contraindicated due to acetaminophen toxicity risk and impaired hydrocodone metabolism.
No specific dosage adjustment is recommended for hepatic impairment per manufacturer; however, caution is advised.
Not recommended for pediatric use (no safety and efficacy data established).
Safety and efficacy have not been established in children under 10 years of age. For children ≥10 years, adult dosing can be considered.
Start at low end of dosing range (1 tablet every 6 hours) due to increased sensitivity, reduced renal function, and risk of cognitive impairment.
Elderly patients may be more sensitive to CNS effects; start at lower end of dosing range (100 mg three times daily) and monitor carefully.
Risk of respiratory depression, especially in children; contraindicated for postoperative pain management in children after tonsillectomy/adenoidectomy; contraindicated in children <12 years, and in children <18 years with risk factors for respiratory depression.
None
Respiratory depression; ultra-rapid metabolizers of CYP2D6 at risk of morphine toxicity; use in breastfeeding may cause infant opioid toxicity; anticholinergic effects of homatropine; risk of abuse and dependence; CNS depression with other depressants.
Severe allergic reactions (e.g., bronchospasm, laryngospasm, cardiovascular collapse) have been reported, especially with chewing or sucking capsules.,Capsules must be swallowed whole to avoid oral mucosal anesthesia and choking hazard.,Use with caution in patients with hypersensitivity to ester-type local anesthetics.,Safety and efficacy in children <10 years not established.
Hypersensitivity to codeine or homatropine; respiratory depression; acute or severe bronchial asthma; GI obstruction; paralytic ileus; children <12 years; children <18 years with tonsillectomy/adenoidectomy; use with MAOIs or within 14 days; breastfeeding women with CYP2D6 ultrarapid metabolism.
Hypersensitivity to benzonatate or related compounds (e.g., tetracaine, procaine)
Grapefruit juice may inhibit CYP2D6 and reduce codeine conversion to morphine, potentially decreasing efficacy. High-fat meals may delay absorption of codeine. Avoid alcohol.
No significant food interactions. The manufacturer does not list any specific dietary restrictions, but alcohol may enhance central nervous system side effects such as drowsiness.
Based on available data, codeine is pregnancy category C. First trimester: Avoid due to possible association with congenital malformations (e.g., cardiovascular defects) from retrospective studies, though risk is low. Second and third trimesters: Risk of neonatal respiratory depression if used near term; chronic use may lead to neonatal withdrawal syndrome. Avoid if possible.
FDA Pregnancy Category C. First trimester: No adequate human studies; animal studies not available. Theoretical risk of fetal bradycardia and respiratory depression if used near term. Second and third trimesters: Avoid use due to potential for neonatal apnea and withdrawal; benzonatate is a local anesthetic with CNS depressant effects.
Codeine is excreted into breast milk. M/P ratio is approximately 2.5. Use with caution due to risk of infant CNS depression, especially in mothers who are CYP2D6 ultra-rapid metabolizers. AAP recommends lowest effective dose for shortest duration; monitor infant for drowsiness, difficulty breathing, or poor feeding.
No data on excretion in human milk; M/P ratio unknown. Benzonatate and its metabolites may be present in breast milk. Caution advised due to potential for infant CNS depression and apnea. Consider benefit of breastfeeding vs risk of drug exposure.
No standard dose adjustment required, but avoid use in third trimester due to risk of neonatal respiratory depression. If used, use lowest effective dose for shortest duration. Monitor for signs of maternal respiratory depression; consider reduced dose in patients with decreased respiratory reserve.
No pharmacokinetic studies in pregnancy. Dose adjustments not established. Use lowest effective dose if necessary. Avoid in third trimester due to neonatal risk. Increased plasma volume may reduce drug levels, but lack of data prevents formal dose adjustment recommendations.
CODEPREX (codeine/guaifenesin) is a combination antitussive/expectorant. Codeine is a prodrug metabolized by CYP2D6 to morphine; ultra-rapid metabolizers risk toxicity. Avoid in children <18 years due to respiratory depression risk. Use with caution in patients with COPD or respiratory insufficiency. Constipation is common; consider prophylactic laxatives.
Benzonatate is a peripherally acting antitussive that anesthetizes stretch receptors in the respiratory tract. Onset of action is within 15-20 minutes and lasts 3-8 hours. Capsules must be swallowed whole; chewing or sucking can cause oropharyngeal anesthesia and choking hazard. Use with caution in patients with a history of drug allergy to tetracaine or other ester-type anesthetics. It is contraindicated in children under 10 years due to increased risk of adverse effects. Overdose can cause seizures, cardiac arrest, and death; treatment is supportive with no specific antidote.
Do not exceed recommended dose; may cause drowsiness, avoid driving or operating machinery until you know how this medication affects you.,Avoid alcohol and other CNS depressants as they increase sedation and respiratory depression risk.,Do not use in children under 18 years of age due to risk of serious breathing problems.,Contact your doctor if cough persists for more than 7 days or is accompanied by fever, rash, or persistent headache.,May cause constipation; increase fluid and fiber intake, and consider a stool softener if needed.,Store at room temperature away from moisture and heat.
Swallow the capsule whole; do not chew, suck, or crush it, as this can cause numbness in your mouth or throat and increase risk of choking.,Take the medication exactly as prescribed; do not take more than directed.,This medication may cause dizziness or drowsiness; avoid driving or operating machinery until you know how it affects you.,Contact your doctor if your cough persists for more than 5 days, or if it is accompanied by fever, rash, or persistent headache.,Keep out of reach of children; accidental ingestion can be fatal in children under 10.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CODEPREX vs BENZONATATE, answered by our medical review team.
CODEPREX is a Antitussive Combination that works by Codeine is a prodrug converted to morphine via CYP2D6; morphine acts as a mu-opioid receptor agonist, while homatropine is an anticholinergic that reduces respiratory secretions.. BENZONATATE is a Antitussive that works by Benzonatate is a local anesthetic structurally related to tetracaine. It suppresses cough by anesthetizing stretch receptors in the respiratory tract, reducing the cough reflex.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CODEPREX and BENZONATATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CODEPREX is: Adults: 1 tablet (containing 5 mg hydrocodone and 325 mg acetaminophen) orally every 4-6 hours as needed for pain; maximum 6 tablets per day.. The standard adult dose of BENZONATATE is: 100 mg to 200 mg orally three times daily as needed for cough.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CODEPREX and BENZONATATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CODEPREX is classified as Category C. Based on available data, codeine is pregnancy category C. First trimester: Avoid due to possible association with congenital malformations (e.g., cardiovascular defects) from retro. BENZONATATE is classified as Category A/B. FDA Pregnancy Category C. First trimester: No adequate human studies; animal studies not available. Theoretical risk of fetal bradycardia and respiratory depression if used near te. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.